Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
Key Highlights
- ➤Q3 revenue $3.10 billion, up 10.0% year over year
- ➤Q3 reported diluted EPS $2.78, up 28.7% year over year
- ➤Q3 adjusted diluted EPS $3.00, up 15.4% year over year
- ➤2026 revenue guidance raised to $12.065 billion-$12.105 billion
- ➤2026 adjusted EPS guidance raised to $11.25-$11.35
Expert Statements
Jim Davis, Chairman, CEO and President of Quest Diagnostics
“We delivered revenue growth of 10% and adjusted EPS growth of over 15% on continued strength across our physician, hospital and consumer channels, complemented by productivity gains from automation and AI.”
Jim Davis, Chairman, CEO and President of Quest Diagnostics
“Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are raising our revenue and EPS guidance for the full year.”
Quest Diagnostics Reports Third Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026 PR Newswire
* Third quarter revenues of $3.10 billion, up 10.0% from 2025, on strong organic revenue growth * Third quarter reported diluted earnings per share ("EPS") of $2.78, up 28.7% from 2025; and adjusted diluted EPS of $3.00, up 15.4% from 2025 * Full year 2026 revenues now expected to be between $12.065 billion and $12.105 billion * Full year 2026 reported diluted EPS now expected to be between $10.21 and $10.31; and adjusted diluted EPS expected to be between $11.25 and $11.35 SECAUCUS, N.J., Oct. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.